Cutler Group LP Arvinas, Inc. Put Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 Apr 19, 2024	BUY	$36.38 - $52.31 $32,742 - $47,079	900 Added 300.0%	1,200 $7,000
Q4 2023 Jan 18, 2024	BUY	$14.19 - $42.33 $4,257 - $12,699	300 New	300 $0
Q4 2022 Feb 07, 2023	BUY	$32.47 - $57.24 $139,621 - $246,132	4,300 New	4,300 $14,000
Q1 2022 Apr 14, 2022	SELL	$60.27 - $81.57 $96,432 - $130,511	-1,600 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$73.2 - $107.87 $36,600 - $53,935	500 Added 45.45%	1,600 $17,000
Q1 2021 Apr 26, 2021	SELL	$58.19 - $91.37 $168,751 - $264,973	-2,900 Reduced 72.5%	1,100 $0
Q4 2020 Jan 21, 2021	BUY	$20.19 - $84.93 $68,646 - $288,762	3,400 Added 566.67%	4,000 $5,000
Q3 2020 Oct 27, 2020	SELL	$22.99 - $36.34 $13,793 - $21,804	-600 Reduced 50.0%	600 $12,000
Q2 2020 Jul 22, 2020	BUY	$29.88 - $56.74 $14,940 - $28,370	500 Added 71.43%	1,200 $10,000
Q1 2020 May 07, 2020	BUY	$33.0 - $54.5 $23,100 - $38,150	700 New	700 $4,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.